Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 3Neoplasms, Plasma Cell 1

Interventions

Lenalidomide 6Dexamethasone 6Cyclophosphamide 5Bortezomib 5fludarabine 3carfilzomib 3belantamab mafodotin 3pomalidomide 2fludarabine phosphate 2Melphalan 2Etoposide 2pembrolizumab 1isatuximab 1elotuzumab 1daratumumab 1Whole-Body Irradiation 1Thalidomide 1Tacrolimus 1Sirolimus 1Resistance Training 1Radiotherapy 1Pharmaceutical Preparations 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Mycophenolic Acid 1Methotrexate 1Exercise 1Equipment and Supplies 1Doxorubicin 1Cyclosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × Thalidomide × 90 days × Clear all
NCT00871013 2026-05-11

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

University of Arkansas

Phase 2 Active not recruiting
160 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡